{"filing":{"accession_number":"0001398733-26-000041","cik":"0001398733","ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"aqst-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/aqst-20260811.htm"},"events":[{"id":26934,"run_id":24498,"accession_number":"0001398733-26-000041","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Aquestive Therapeutics reported second quarter 2026 financial results, including total revenues of $13.8 million (up 38% year-over-year), net loss of $22.9 million, and cash position of $98.5 million, along with operational updates on key programs including Anaphylm NDA resubmission and AQST-108 development.","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28236,"accession_number":"0001398733-26-000041","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Aquestive's second quarter 2026 financial results, including total revenues of $13.8 million (up 38% YoY), net loss of $22.9 million, and cash position of $98.5 million. The press release (Exhibit 99.1) provides detailed financial statements and operational updates on key programs including Anaphylm NDA resubmission and AQST-108 development. This is a standard earnings release disclosure material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:21.477117+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28237,"accession_number":"0001398733-26-000041","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation, but the supplemental exhibits include EX-99.1, which is a formal earnings release titled \"Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update.\" The earnings release discloses Q2 2026 financial results (total revenues of $13.8 million, net loss of $22.9 million), detailed segment performance, and material operational updates regarding the Anaphylm NDA resubmission and pipeline programs. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:21.477117+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28236,"accession_number":"0001398733-26-000041","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Aquestive's second quarter 2026 financial results, including total revenues of $13.8 million (up 38% YoY), net loss of $22.9 million, and cash position of $98.5 million. The press release (Exhibit 99.1) provides detailed financial statements and operational updates on key programs including Anaphylm NDA resubmission and AQST-108 development. This is a standard earnings release disclosure material to investors assessing the company's financial performance and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:21.477117+00:00","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-08-11"},{"id":28237,"accession_number":"0001398733-26-000041","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation, but the supplemental exhibits include EX-99.1, which is a formal earnings release titled \"Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update.\" The earnings release discloses Q2 2026 financial results (total revenues of $13.8 million, net loss of $22.9 million), detailed segment performance, and material operational updates regarding the Anaphylm NDA resubmission and pipeline programs. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:21.477117+00:00","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-08-11"}]}